PT  - JOURNAL ARTICLE
AU  - Lei-Ke Zhang
AU  - Yuan Sun
AU  - Haolong Zeng
AU  - Yudong Peng
AU  - Xiaming Jiang
AU  - Wei-Juan Shang
AU  - Yan Wu
AU  - Shufen Li
AU  - Yu-Lan Zhang
AU  - Liu Yang
AU  - Hongbo Chen
AU  - Runming Jin
AU  - Wei Liu
AU  - Hao Li
AU  - Ke Peng
AU  - Gengfu Xiao
TI  - Calcium channel blocker amlodipine besylate is associated with reduced case fatality rate of COVID-19 patients with hypertension
AID  - 10.1101/2020.04.08.20047134
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.08.20047134
4099  - http://medrxiv.org/content/early/2020/04/14/2020.04.08.20047134.short
4100  - http://medrxiv.org/content/early/2020/04/14/2020.04.08.20047134.full
AB  - The coronavirus disease (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has now spread to more than 100 countries posing as a serious threat to the public health on a global scale. Patients with comorbidity such as hypertension suffer more severe infection with elevated case fatality rate. Development of effective anti-viral drug is in urgent need to treat COVID-19 patients. Here we report that calcium channel blockers (CCBs), a type of anti-hypertension drugs that are widely used in the clinics, can significantly inhibit the post-entry replication events of SARS-CoV-2 in vitro. Comparison with two other major types of anti-hypertension drugs, the angiotensin converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB), showed that only CCBs display significant anti-SARS-CoV-2 efficacy. Combined treatment with chloroquine and CCBs significantly enhanced the anti-SARS-CoV-2 efficacy. Retrospective clinical investigation of COVID-19 patients revealed that the CCB amlodipine besylate administration was associated with reduced case fatality rate of patients with hypertension. Results from this study suggest that CCB administration for COVID-19 patients with hypertension as the comorbidity might improve the disease outcome.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was supported by the Natural Science Foundation of China (31970165, 81825019, 81722041, 31770188), the Strategic Priority Research Program of the Chinese Academy of Sciences (XDB29010204), National Science and Technology Major Project (No. 2018ZX10101004001005), and the Hubei Science and Technology Project (2020FCA003).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data in the study are available from the corresponding author by request